Trial results

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

NCT06577090 on ClinicalTrials.gov · last registry update 2026-01-14

Closed to new participants; the 136 already enrolled are still being followed. Due to report 20 November 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Percent change in body weight (main study). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 22 August 2024 — 2 years so far. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Skye Bioscience, Inc.

Sponsor type

Industry

Enrollment

136

Started

2024-08-22

Primary completion

2026-11-20 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent change in body weight (main study)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.